This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer

This study has been completed.
Information provided by (Responsible Party):
Lin Yang, Chinese Academy of Medical Sciences Identifier:
First received: February 6, 2012
Last updated: December 3, 2014
Last verified: December 2014
The purpose of this study is to determine the efficacy and safety of oxaliplatin and s1 as first-line treatment of advanced gastric cancer.

Condition Intervention Phase
Stomach Neoplasms Drug: Oxaliplatin Drug: s1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: a Phase II Study of Oxaliplatin Plus S-1 (SOX) as First-line Treatment for Patients With Advanced Gastric Cancer

Resource links provided by NLM:

Further study details as provided by Lin Yang, Chinese Academy of Medical Sciences:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 2 years ]
    from date of treatment was administered until the date of first documented progression or death from any cause whichever first, assessed every 6 weeks

Secondary Outcome Measures:
  • Response Rate [ Time Frame: 2 years ]
    From date of treatment was administered until the date of first documented response to treatment according to RECIST criteria,assessed every 2 cycles

  • overall survival [ Time Frame: 2 years ]
    From date of treatment was administered until the date of death from any cause,assessed every 3 months

  • number of participants with adverse events [ Time Frame: 2 years ]
    assessed from treatment was administered until 1 months after withdrawing from study

Enrollment: 43
Study Start Date: June 2011
Study Completion Date: June 2013
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: treatment
Drug: Oxaliplatin
130mg/m2 d1,repeated q21d
Other Name: eloxatin
Drug: s1
80mg/m2/d, d1-14,repeated q21d
Other Name: TS-1

Detailed Description:
There was no evidence of standard chemotherapy for advanced gastric cancer (AGC) in China. Fluoropyrimidines and cisplatin have been widely used in a variety of combinations in the treatment of AGC. Capecitabine/cisplatin combination therapy showed an overall response rate (ORR) of 41- 55%, a median time to progression/progression free survival (TTP/PFS) of 5.6-6.3 months, and a median overall survival (OS) of 10.1-10.5 months. Though no studies have compared two oral fluoropyrimidines in combination with oxaliplatin, both S-1 and capecitabine appear to be comparable in terms of efficacy and safety. The investigators conducted a phase II trial of oxaliplatin combined with S-1 in the treatment of first-line AGC.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven in operable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapse gastric adenocarcinoma
  • Measurable lesion and/or non-measurable lesion defined by RECIST
  • ECOG performance status ≦ 1
  • Hgb ≧ 8g/dL, WBC 4000-12000/mm3, platelets ≧ 100,000/mm3
  • Creatine ≦ upper normal limit (UNL)
  • Total bilirubin ≦ 1.5 X UNL
  • AST, ALT and ALP ≦ 2.5 x UNL

    • Subjects must be able to take orally
  • No prior chemotherapy
  • Life expectancy estimated than 3 months
  • Written informed consent

Exclusion Criteria:

  • Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant

    • Known brain metastases
    • History of hypersensitivity to fluoropyrimidines, oxaliplatin
  • Active double cancer
  • Treatment with any investigational product during the last 4 weeks prior to study entry
  • Symptomatic peripheral neuropathy ≧ garde 2. by NCI-CTCAE ver.3.0
  • Any previous chemotherapy or radiotherapy for AGC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01531452

China, Beijing
cancer hospital & Institute,Chinese Academy of Medical Sciences
Beijing, Beijing, China, 100021
Sponsors and Collaborators
Chinese Academy of Medical Sciences
Principal Investigator: Jinwan Wang, MD cancer hospital&institute,Chinese Academy of Medical Sciences
  More Information

Responsible Party: Lin Yang, MD, Chinese Academy of Medical Sciences Identifier: NCT01531452     History of Changes
Other Study ID Numbers: CH-GI-016
Study First Received: February 6, 2012
Last Updated: December 3, 2014

Keywords provided by Lin Yang, Chinese Academy of Medical Sciences:
Stomach Neoplasms
drug therapy

Additional relevant MeSH terms:
Stomach Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Antineoplastic Agents processed this record on August 18, 2017